First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile; VECTRA trial will ...
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore ...
Enrollment began in the U.S. in June 2022 and expanded to China, New Zealand, Australia, and India. The topline results summary reports 659 patients: 164 assigned to CBT-001 0.1%, 329 to CBT-001 0.2%, ...
In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm AIHA (“wAIHA”) are currently under regulatory review by the National Medical Products Administration (NMPA), supported ...
Total revenue for the third quarter was $302.3 million, an increase of $73.2 million or 32.0% over the prior year quarter; Net income for the third quarter was $9.6 million, an increase of $3.6 ...
NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease.
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 ...
Agreement reinforces Boehringer Ingelheim’s long-term commitment to China’s innovation ecosystem and validates SBP Group’s innovative R&D capabilities Ingelheim, Germany, and Hong Kong/China, 4 ...
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results